Over the last three years, there have been eight cancer cell therapy M&A deals for advanced first generation and next gen cancer cell therapy companies. Six of them have been completed to date. Data for this analysis was compiled using the DealForma biopharma deals database. We applied initial filters for mergers and acquisitions of companies developing cell therapies for cancer and excluded terminated acquisition offers. From there, we exported the data to Excel, segmented the list by whether the target company’s cell therapy would be considered first generation or next gen, and used pivot tables and charts to do the rest. All data are based on publicly disclosed figures. We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
As the 38th annual J.P. Morgan Healthcare Conference approached, we used the DealForma deals database to evaluate the recent M&A activity in the cancer cell therapy space. With Yescarta axicabtagene ciloleucel and Kymriah tisagenlecleucel now on the market for two years, cell immunotherapies are one of the newest forms of treatment that helps the immune system fight cancer. We identified eight total cancer cell therapy-focused acquisitions announced in the last three years, six of which have been completed and are highlighted below in order based on deal value. Included in the broader cell therapy analysis that follows were M&A’s, reverse mergers, exercised acquisition options and partnerships with an acquisition option. Terminated acquisition offers were excluded, and Bristol-Myers Squibb’s $74 billion acquisition of Celgene was charted separately.
Gilead Sciences acquired Kite Pharma
- Date Announced: August 28, 2017
- Total Deal Value: $11.9 billion
- Target Stage at Acquisition: Phase III
- Main Asset at Acquisition: Yescarta (chimeric antigen receptor (CAR) T therapy)
Celgene acquired Juno Therapeutics
- Date Announced: January 22, 2018
- Total Deal Value: $9 billion
- Target Stage at Acquisition: Phase II
- Main Asset at Acquisition: JCAR017 (lisocabtagene maraleucel; liso-cel) – CAR-T therapy
Astellas Pharma acquired Xyphos Biosciences
- Date Announced: December 26, 2019
- Total Deal Value: $665 million
- Target Stage at Acquisition: Preclinical/IND
- Main Asset at Acquisition: “convertibleCAR-T” cell product, ACCEL (Advanced Cellular Control through Engineered Ligands) technology platform
Gilead, Kite acquired Cell Design Labs
- Date Announced: December 7, 2017
- Total Deal Value: $567 million
- Target Stage at Acquisition: Platform/Discovery
- Main Asset at Acquisition: synNotch and Throttle technology platforms for CAR-T cells
Astellas acquired Universal Cells
- Date Announced: February 13, 2018
- Total Deal Value: $102.5 million
- Target Stage at Acquisition: Preclinical/IND
- Main Asset at Acquisition: Universal Donor Stem Cell technology
Kiadis acquired CytoSen Therapeutics
- Date Announced: April 17, 2019
- Total Deal Value: Not Disclosed
- Target Stage at Acquisition: Phase III
- Main Asset at Acquisition: ATIR101 (Allodepleted T-cell immunotherapy, discontinued development as of November 2019); CSDT002-NK (natural killer-cell therapy)
Two M&A option deals that are yet to be exercised are Kite’s research partnership and an option to acquire Gadeta, and Millennium Pharmaceuticals’ (Takeda Oncology) research partnership and option to acquire GammaDelta Therapeutics.
Using DealForma’s deals database, we also evaluated M&A trends over the past decade of companies developing first and next generation cell therapy, gene therapy, other immuno-oncology therapies, and small molecules for cancer.
These figures are available for download below.
Finally, we compared the macro-trends of cancer immunotherapy/cell therapy M&A field with other technology fields including small molecules, diagnostics and gene therapy/vectors.
Want data for your analysis? Want us to do it? Subscribers get both.
Schedule your demo of the DealForma database to see how we help you get better reports done faster.
22,968
Deal Profiles
12,034
Funding Rounds
23,805
Company Profiles
15,292
Product Profiles
119K+
Clinical Trials
3,386
Business Developers
Specifically for Biotech, Pharma, Device, and Diagnostics
Marie Daghlian is a freelance writer and editor who reports on the business of biotechnology and healthcare technologies and on rare diseases for Global Gene’s Rare Daily. She also covers the industry for Big4Bio, a daily newsletter focused on the four major biotech centers in the United States.
More Research by DealForma
Biopharma Deal of the Month: Vir – GSK for VIR-2482 and mAbs for Influenza
Vir Biotechnology and GSK expanded their partnership with a new deal to develop VIR-2482 and mAbs for influenza. This was the largest upfront cash and equity for a partnership signed in Feb. 2021.
Biotech and Pharma M&A in 2020
Biotech and pharma M&A total deal values slumped in 2020, despite an active year in life sciences dealmaking, with no big standout biopharma deals until late in the second half of the year. We look at the extensive DealForma database to see how life sciences M&A activity shaped up in 2020 in more detail.
Life Sciences M&A Tops $240 Billion in 2019
This article is a sample from the DealForma Annual Deal Trends Report provided to database subscribers. Data for this analysis was compiled using the DealForma biopharma deals database. We applied initial filters for mergers and acquisitions, therapeutic areas, asset...
Gene Therapy Deals, M&A, and Venture Funding
We looked at 10 years of gene therapy deals, M&A, venture funding, and academic partnerships for an article by John Carroll at Endpoints News.
Reverse Mergers in Biopharma
Biotech reverse mergers have been an alternate way for private biotechnology companies to gain a public listing. Here’s a quick table of over 10 years of deals.
Biopharma Partnering Sets Records in Q1 2019 after a Strong 2018
2019 biopharma dealmaking started with a bang as the first quarter saw global biotech and pharma partnering deal values hit $38 billion in 282 deals.
Top 10 Venture Round Investors in Cancer Therapeutics
Celgene was among the top investors in cancer biotech companies. This is a look at the top 10 since 2010.
Life Sciences M&A Starts with a Bang in 2019 after Rebounding in 2018
Life Sciences M&A started with a bang in 2019 with one of the biggest deals to date – Bristol-Myers Squibb will acquire Celgene for $74 billion. We mined DealForma’s extensive database for historical M&A trends in biopharma, medical devices, and diagnostics to get an idea of what might lie ahead in 2019.
Oncology Partnering Deal Trends: Early Stage Deals Dominate with Highest Potential Deal Values
Innovative biotech companies are in a stronger position today as far as the value of their assets. We look at oncology deal payments by stage at signing.
Top Investors in Biotech Venture Rounds
Global biotechnology venture investment topped $11.8 billion in 258 financing rounds in the first 10 months of 2018. Who are the top biotech venture investors, where are they investing their money, and what are they investing in?
You met on Zoom. Now it's Deal Time.
With thousands of company profiles and a decade of deals specifically in biopharma and medtech, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.